Timing of oral anticoagulation in atrial fibrillation patients after acute ischaemic stroke and outcome after 3 months: results of the multicentre Berlin Atrial Fibrillation Registry

IF 2.8 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Open Heart Pub Date : 2024-09-01 DOI:10.1136/openhrt-2024-002688
Manuel C Olma, Serdar Tütüncü, Katrin Hansen, Ulrike Grittner, Claudia Kunze, Joanna Dietzel, Johannes Schurig, Boris Dimitrijeski, Georg Hagemann, Frank Hamilton, Martin Honermann, Gerhard Jan Jungehuelsing, Andreas Kauert, Hans-Christian Koennecke, Bruno-Marcel Mackert, Darius G Nabavi, Ingo Schmehl, Paul Sparenberg, Robert Stingele, Enrico Voelzke, Carolin Waldschmidt, Daniel Zeise-Wehry, Peter U Heuschmann, Matthias Endres, Karl Georg Haeusler
{"title":"Timing of oral anticoagulation in atrial fibrillation patients after acute ischaemic stroke and outcome after 3 months: results of the multicentre Berlin Atrial Fibrillation Registry","authors":"Manuel C Olma, Serdar Tütüncü, Katrin Hansen, Ulrike Grittner, Claudia Kunze, Joanna Dietzel, Johannes Schurig, Boris Dimitrijeski, Georg Hagemann, Frank Hamilton, Martin Honermann, Gerhard Jan Jungehuelsing, Andreas Kauert, Hans-Christian Koennecke, Bruno-Marcel Mackert, Darius G Nabavi, Ingo Schmehl, Paul Sparenberg, Robert Stingele, Enrico Voelzke, Carolin Waldschmidt, Daniel Zeise-Wehry, Peter U Heuschmann, Matthias Endres, Karl Georg Haeusler","doi":"10.1136/openhrt-2024-002688","DOIUrl":null,"url":null,"abstract":"Background Oral anticoagulation (OAC) is key in stroke prevention in patients with atrial fibrillation (AF) but there is uncertainty regarding the optimal timing of OAC (re)initiation after stroke, as recent large randomised controlled trials have methodological weaknesses and excluded stroke patients on therapeutic anticoagulation at stroke onset as well as patients started on a vitamin K antagonist after stroke. The ‘1–3–6–12 days rule’, based on expert consensus and referring to stroke severity, was used in clinical practice to initiate OAC after acute ischaemic stroke or transient ischaemic attack (TIA) since publication in 2013. Methods We retrospectively assessed whether compliance to the ‘1–3–6–12 days rule’ was associated with the composite endpoint (recurrent stroke, systemic embolism, myocardial infarction, major bleeding or all-cause death). Results Among 708 registry patients with known AF before stroke and hospitalisation within 72 hours after stroke, 432 were anticoagulated at stroke onset. OAC was started according to the ‘1–3–6–12 days rule’ in 255 (39.2%) patients. Non-adherence to the ‘1–3–6–12 days rule’ was not associated with the composite endpoint within 3 months in 661 patients who (re-)started on OAC (log-rank test: p=0.74). Results were similar for 521 patients (re)started on a non-vitamin K-dependent OAC. Conclusion (Re)starting OAC after stroke followed the ‘1–3–6–12 days rule’ in about 40% of all patients with AF, and more often in those anticoagulated at stroke onset. Adherence to the ‘1–3–6–12 days rule’ did not reduce the composite clinical endpoint, if OAC was restarted within 3 months of stroke/TIA. Trial registration number [NCT02306824][1]. Data are available on reasonable request. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT02306824&atom=%2Fopenhrt%2F11%2F2%2Fe002688.atom","PeriodicalId":19505,"journal":{"name":"Open Heart","volume":"190 1","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Heart","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/openhrt-2024-002688","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background Oral anticoagulation (OAC) is key in stroke prevention in patients with atrial fibrillation (AF) but there is uncertainty regarding the optimal timing of OAC (re)initiation after stroke, as recent large randomised controlled trials have methodological weaknesses and excluded stroke patients on therapeutic anticoagulation at stroke onset as well as patients started on a vitamin K antagonist after stroke. The ‘1–3–6–12 days rule’, based on expert consensus and referring to stroke severity, was used in clinical practice to initiate OAC after acute ischaemic stroke or transient ischaemic attack (TIA) since publication in 2013. Methods We retrospectively assessed whether compliance to the ‘1–3–6–12 days rule’ was associated with the composite endpoint (recurrent stroke, systemic embolism, myocardial infarction, major bleeding or all-cause death). Results Among 708 registry patients with known AF before stroke and hospitalisation within 72 hours after stroke, 432 were anticoagulated at stroke onset. OAC was started according to the ‘1–3–6–12 days rule’ in 255 (39.2%) patients. Non-adherence to the ‘1–3–6–12 days rule’ was not associated with the composite endpoint within 3 months in 661 patients who (re-)started on OAC (log-rank test: p=0.74). Results were similar for 521 patients (re)started on a non-vitamin K-dependent OAC. Conclusion (Re)starting OAC after stroke followed the ‘1–3–6–12 days rule’ in about 40% of all patients with AF, and more often in those anticoagulated at stroke onset. Adherence to the ‘1–3–6–12 days rule’ did not reduce the composite clinical endpoint, if OAC was restarted within 3 months of stroke/TIA. Trial registration number [NCT02306824][1]. Data are available on reasonable request. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT02306824&atom=%2Fopenhrt%2F11%2F2%2Fe002688.atom
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
急性缺血性中风后心房颤动患者口服抗凝药的时机和 3 个月后的预后:柏林心房颤动多中心登记的结果
背景 口服抗凝疗法(OAC)是心房颤动(AF)患者预防卒中的关键,但由于近期的大型随机对照试验在方法学上存在缺陷,且排除了卒中发病时正在接受治疗性抗凝疗法的卒中患者以及卒中后开始服用维生素 K 拮抗剂的患者,因此卒中后(再次)启动 OAC 的最佳时机尚不确定。基于专家共识并参考卒中严重程度的 "1-3-6-12 天规则 "自 2013 年发布以来一直用于临床实践,以在急性缺血性卒中或短暂性脑缺血发作(TIA)后启动 OAC。方法 我们回顾性评估了遵守 "1-3-6-12 天规则 "是否与复合终点(复发性卒中、全身性栓塞、心肌梗死、大出血或全因死亡)相关。结果 在中风前已知房颤、中风后 72 小时内住院的 708 名登记患者中,有 432 人在中风发作时接受了抗凝治疗。255名患者(39.2%)按照 "1-3-6-12天规则 "开始使用OAC。在(重新)开始使用 OAC 的 661 名患者中,不遵守 "1-3-6-12 天规则 "与 3 个月内的复合终点无关(对数秩检验:P=0.74)。521名(重新)开始使用非维生素K依赖型OAC的患者的结果类似。结论 在所有房颤患者中,约 40% 的患者在中风后(重新)开始使用 OAC 时遵循了 "1-3-6-12 天规则",而在中风发作时接受抗凝治疗的患者中更常见。如果在中风/TIA发生后3个月内重新开始使用OAC,遵守 "1-3-6-12天规则 "并不会降低综合临床终点。试验注册号[NCT02306824][1]。如有合理要求,可提供数据。[1]:/lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT02306824&atom=%2Fopenhrt%2F11%2F2%2Fe002688.atom
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Open Heart
Open Heart CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
4.60
自引率
3.70%
发文量
145
审稿时长
20 weeks
期刊介绍: Open Heart is an online-only, open access cardiology journal that aims to be “open” in many ways: open access (free access for all readers), open peer review (unblinded peer review) and open data (data sharing is encouraged). The goal is to ensure maximum transparency and maximum impact on research progress and patient care. The journal is dedicated to publishing high quality, peer reviewed medical research in all disciplines and therapeutic areas of cardiovascular medicine. Research is published across all study phases and designs, from study protocols to phase I trials to meta-analyses, including small or specialist studies. Opinionated discussions on controversial topics are welcomed. Open Heart aims to operate a fast submission and review process with continuous publication online, to ensure timely, up-to-date research is available worldwide. The journal adheres to a rigorous and transparent peer review process, and all articles go through a statistical assessment to ensure robustness of the analyses. Open Heart is an official journal of the British Cardiovascular Society.
期刊最新文献
Hypertrophic cardiomyopathy due to truncating variants in myosin binding protein C: a Spanish cohort. Composition of cardiac troponin release differs after marathon running and myocardial infarction. Association of prior tuberculosis with cardiovascular status in perinatally HIV-1-infected adolescents. Myocarditis after COVID-19 and influenza infections: insights from a large data set. Spectrum of hereditary transthyretin amyloidosis due to T60A(p.Thr80Ala) variant in an Irish Amyloidosis Network.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1